JP2002519390A - マクロファージ媒介疾患におけるテキサフィリンの使用 - Google Patents

マクロファージ媒介疾患におけるテキサフィリンの使用

Info

Publication number: JP2002519390A
Authority: JP; Japan
Prior art keywords: texaphyrin; macrophage; disease; mediated disease; radiation
Prior art date: 1998-07-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2000557860A

Other languages

English (en)

Japanese (ja)

Inventor

キャサリンダブリュー．ウッドバーン，

スチュアートダブリュー．ヤング，

Original Assignee

ファーマサイクリクス，インコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-06

Filing date

1999-07-06

Publication date

2002-07-02

1999-07-06 Application filed by ファーマサイクリクス，インコーポレイテッド filed Critical ファーマサイクリクス，インコーポレイテッド

2002-07-02 Publication of JP2002519390A publication Critical patent/JP2002519390A/ja

Status Pending legal-status Critical Current

Links

210000002540 macrophage Anatomy 0.000 title claims abstract description 92
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 59
201000010099 disease Diseases 0.000 title claims abstract description 57
230000001404 mediated effect Effects 0.000 title claims abstract description 41
238000000034 method Methods 0.000 claims abstract description 90
238000011282 treatment Methods 0.000 claims abstract description 49
239000003814 drug Substances 0.000 claims abstract description 42
229940124597 therapeutic agent Drugs 0.000 claims abstract description 32
230000000694 effects Effects 0.000 claims abstract description 20
230000001235 sensitizing effect Effects 0.000 claims abstract description 7
208000037803 restenosis Diseases 0.000 claims description 32
239000002246 antineoplastic agent Substances 0.000 claims description 30
229940127089 cytotoxic agent Drugs 0.000 claims description 26
230000005855 radiation Effects 0.000 claims description 26
229910052751 metal Inorganic materials 0.000 claims description 21
239000002184 metal Substances 0.000 claims description 21
208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 20
206010003210 Arteriosclerosis Diseases 0.000 claims description 19
208000024172 Cardiovascular disease Diseases 0.000 claims description 19
238000003384 imaging method Methods 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 9
208000023275 Autoimmune disease Diseases 0.000 claims description 8
208000027866 inflammatory disease Diseases 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 6
230000001225 therapeutic effect Effects 0.000 claims description 6
230000000973 chemotherapeutic effect Effects 0.000 claims description 5
238000002595 magnetic resonance imaging Methods 0.000 claims description 5
230000005298 paramagnetic effect Effects 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 3
208000035475 disorder Diseases 0.000 claims description 2
230000003013 cytotoxicity Effects 0.000 abstract description 6
231100000135 cytotoxicity Toxicity 0.000 abstract description 6
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 32
210000001519 tissue Anatomy 0.000 description 32
238000002399 angioplasty Methods 0.000 description 26
210000001367 artery Anatomy 0.000 description 23
210000004027 cell Anatomy 0.000 description 23
238000002604 ultrasonography Methods 0.000 description 22
206010028980 Neoplasm Diseases 0.000 description 18
230000006378 damage Effects 0.000 description 18
230000002792 vascular Effects 0.000 description 18
238000002347 injection Methods 0.000 description 17
239000007924 injection Substances 0.000 description 17
241001465754 Metazoa Species 0.000 description 16
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
229960004679 doxorubicin Drugs 0.000 description 16
238000002428 photodynamic therapy Methods 0.000 description 16
AARXZCZYLAFQQU-UHFFFAOYSA-N motexafin gadolinium Chemical compound [Gd].CC(O)=O.CC(O)=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 AARXZCZYLAFQQU-UHFFFAOYSA-N 0.000 description 15
241000283973 Oryctolagus cuniculus Species 0.000 description 14
-1 benzoporphyrin derivative compounds Chemical class 0.000 description 13
239000003795 chemical substances by application Substances 0.000 description 13
230000003902 lesion Effects 0.000 description 11
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
210000004204 blood vessel Anatomy 0.000 description 10
210000004351 coronary vessel Anatomy 0.000 description 10
239000001301 oxygen Substances 0.000 description 10
229910052760 oxygen Inorganic materials 0.000 description 10
239000000243 solution Substances 0.000 description 10
241000700159 Rattus Species 0.000 description 9
150000001768 cations Chemical class 0.000 description 9
230000003034 chemosensitisation Effects 0.000 description 9
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
229930195725 Mannitol Natural products 0.000 description 8
229940079593 drug Drugs 0.000 description 8
208000014674 injury Diseases 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
239000000594 mannitol Substances 0.000 description 8
235000010355 mannitol Nutrition 0.000 description 8
239000002245 particle Substances 0.000 description 8
201000001320 Atherosclerosis Diseases 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
210000001715 carotid artery Anatomy 0.000 description 7
235000012000 cholesterol Nutrition 0.000 description 7
210000003090 iliac artery Anatomy 0.000 description 7
238000001361 intraarterial administration Methods 0.000 description 7
210000003127 knee Anatomy 0.000 description 7
239000003504 photosensitizing agent Substances 0.000 description 7
206010039073 rheumatoid arthritis Diseases 0.000 description 7
210000000329 smooth muscle myocyte Anatomy 0.000 description 7
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
238000001514 detection method Methods 0.000 description 6
206010020718 hyperplasia Diseases 0.000 description 6
230000003834 intracellular effect Effects 0.000 description 6
239000002534 radiation-sensitizing agent Substances 0.000 description 6
238000001959 radiotherapy Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
206010048610 Cardiotoxicity Diseases 0.000 description 5
208000027418 Wounds and injury Diseases 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
206010003246 arthritis Diseases 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
231100000259 cardiotoxicity Toxicity 0.000 description 5
239000006114 chemosensitizer Substances 0.000 description 5
231100000433 cytotoxic Toxicity 0.000 description 5
230000001472 cytotoxic effect Effects 0.000 description 5
239000012530 fluid Substances 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
229910052739 hydrogen Inorganic materials 0.000 description 5
150000004032 porphyrins Chemical class 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
206010002383 Angina Pectoris Diseases 0.000 description 4
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000001168 carotid artery common Anatomy 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
229940044683 chemotherapy drug Drugs 0.000 description 4
238000013461 design Methods 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
210000002744 extracellular matrix Anatomy 0.000 description 4
239000000835 fiber Substances 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
239000002609 medium Substances 0.000 description 4
150000002739 metals Chemical class 0.000 description 4
210000001616 monocyte Anatomy 0.000 description 4
230000002093 peripheral effect Effects 0.000 description 4
230000002165 photosensitisation Effects 0.000 description 4
229910052707 ruthenium Inorganic materials 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
210000001258 synovial membrane Anatomy 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
210000005166 vasculature Anatomy 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
229930012538 Paclitaxel Natural products 0.000 description 3
208000031481 Pathologic Constriction Diseases 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
230000009471 action Effects 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
210000000709 aorta Anatomy 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 3
230000003143 atherosclerotic effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
210000000269 carotid artery external Anatomy 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
230000005292 diamagnetic effect Effects 0.000 description 3
238000009826 distribution Methods 0.000 description 3
150000002431 hydrogen Chemical class 0.000 description 3
TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
239000007951 isotonicity adjuster Substances 0.000 description 3
229960003299 ketamine Drugs 0.000 description 3
210000000629 knee joint Anatomy 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
230000004807 localization Effects 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
230000010534 mechanism of action Effects 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
230000005012 migration Effects 0.000 description 3
238000013508 migration Methods 0.000 description 3
229960004857 mitomycin Drugs 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
WIQKYZYFTAEWBF-UHFFFAOYSA-L motexafin lutetium hydrate Chemical compound O.[Lu+3].CC([O-])=O.CC([O-])=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 WIQKYZYFTAEWBF-UHFFFAOYSA-L 0.000 description 3
238000011587 new zealand white rabbit Methods 0.000 description 3
230000036542 oxidative stress Effects 0.000 description 3
229960001592 paclitaxel Drugs 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
229910052698 phosphorus Inorganic materials 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
230000000637 radiosensitizating effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
208000037804 stenosis Diseases 0.000 description 3
230000002966 stenotic effect Effects 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
230000008733 trauma Effects 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
108010006654 Bleomycin Proteins 0.000 description 2
206010008479 Chest Pain Diseases 0.000 description 2
VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
101710178376 Heat shock 70 kDa protein Proteins 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
206010070834 Sensitisation Diseases 0.000 description 2
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
238000002679 ablation Methods 0.000 description 2
230000004913 activation Effects 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
229940100198 alkylating agent Drugs 0.000 description 2
239000002168 alkylating agent Substances 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
210000002376 aorta thoracic Anatomy 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000027455 binding Effects 0.000 description 2
230000001370 bioreducing effect Effects 0.000 description 2
208000034158 bleeding Diseases 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
229960001561 bleomycin Drugs 0.000 description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
210000004004 carotid artery internal Anatomy 0.000 description 2
230000030833 cell death Effects 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000001218 confocal laser scanning microscopy Methods 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
150000004696 coordination complex Chemical class 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
230000008021 deposition Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000002612 dispersion medium Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
210000001105 femoral artery Anatomy 0.000 description 2
210000000497 foam cell Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000007306 functionalization reaction Methods 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
125000002768 hydroxyalkyl group Chemical group 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005865 ionizing radiation Effects 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
238000013147 laser angioplasty Methods 0.000 description 2
210000002414 leg Anatomy 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229960004961 mechlorethamine Drugs 0.000 description 2
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
244000005700 microbiome Species 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000013307 optical fiber Substances 0.000 description 2
229940092253 ovalbumin Drugs 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
230000002265 prevention Effects 0.000 description 2
229940107685 reopro Drugs 0.000 description 2
102220240796 rs553605556 Human genes 0.000 description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
230000008313 sensitization Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000036262 stenosis Effects 0.000 description 2
230000000153 supplemental effect Effects 0.000 description 2
230000008961 swelling Effects 0.000 description 2
201000004595 synovitis Diseases 0.000 description 2
210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
229910052724 xenon Inorganic materials 0.000 description 2
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 1
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
206010003162 Arterial injury Diseases 0.000 description 1
206010051113 Arterial restenosis Diseases 0.000 description 1
206010060965 Arterial stenosis Diseases 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
101500000959 Bacillus anthracis Protective antigen PA-20 Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
238000004435 EPR spectroscopy Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
206010017711 Gangrene Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
208000011200 Kawasaki disease Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
239000002616 MRI contrast agent Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010059282 Metastases to central nervous system Diseases 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
201000011152 Pemphigus Diseases 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
206010034972 Photosensitivity reaction Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
238000001069 Raman spectroscopy Methods 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
229960000446 abciximab Drugs 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000001780 adrenocortical effect Effects 0.000 description 1
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
230000003872 anastomosis Effects 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
230000006502 antiplatelets effects Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
210000002565 arteriole Anatomy 0.000 description 1
210000001188 articular cartilage Anatomy 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
230000035572 chemosensitivity Effects 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
210000000991 chicken egg Anatomy 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000001427 coherent effect Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
230000005786 degenerative changes Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000371 dose-limiting toxicity Toxicity 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000013156 embolectomy Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000004146 energy storage Methods 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000002073 fluorescence micrograph Methods 0.000 description 1
150000002224 folic acids Chemical class 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
229910052733 gallium Inorganic materials 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
230000009545 invasion Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000004576 lipid-binding Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000005291 magnetic effect Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
231100000682 maximum tolerated dose Toxicity 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
210000004925 microvascular endothelial cell Anatomy 0.000 description 1
230000001617 migratory effect Effects 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
230000003387 muscular Effects 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
239000004084 narcotic analgesic agent Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
231100000065 noncytotoxic Toxicity 0.000 description 1
230000002020 noncytotoxic effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000033116 oxidation-reduction process Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
150000002926 oxygen Chemical class 0.000 description 1
210000004417 patella Anatomy 0.000 description 1
210000000426 patellar ligament Anatomy 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
201000001976 pemphigus vulgaris Diseases 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000036211 photosensitivity Effects 0.000 description 1
208000017983 photosensitivity disease Diseases 0.000 description 1
231100000434 photosensitization Toxicity 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000002243 precursor Substances 0.000 description 1
229960001807 prilocaine Drugs 0.000 description 1
MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
229960003912 probucol Drugs 0.000 description 1
230000002947 procoagulating effect Effects 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229940043274 prophylactic drug Drugs 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000000941 radioactive substance Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
230000015590 smooth muscle cell migration Effects 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000000527 sonication Methods 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000005222 synovial tissue Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
231100000057 systemic toxicity Toxicity 0.000 description 1
230000008685 targeting Effects 0.000 description 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
229910052713 technetium Inorganic materials 0.000 description 1
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000035924 thermogenesis Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
210000002303 tibia Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
238000003325 tomography Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
150000004654 triazenes Chemical class 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000037314 wound repair Effects 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

JP2000557860A 1998-07-06 1999-07-06 マクロファージ媒介疾患におけるテキサフィリンの使用 Pending JP2002519390A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11050998A	1998-07-06	1998-07-06
US09/110,509		1998-07-06
PCT/US1999/015199 WO2000001414A1 (en)	1998-07-06	1999-07-06	Use of texaphyrins in macrophage-mediated disease

Publications (1)

Publication Number	Publication Date
JP2002519390A true JP2002519390A (ja)	2002-07-02

Family

ID=22333401

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2000557860A Pending JP2002519390A (ja)	1998-07-06	1999-07-06	マクロファージ媒介疾患におけるテキサフィリンの使用

Country Status (8)

Country	Link
EP (1)	EP1094840A1 (es)
JP (1)	JP2002519390A (es)
KR (1)	KR20010079498A (es)
AR (1)	AR019226A1 (es)
AU (1)	AU4860899A (es)
CA (1)	CA2336134A1 (es)
NO (1)	NO20010044L (es)
WO (1)	WO2000001414A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6163988A (en) *	1995-05-17	2000-12-26	Rockland, Inc.	Assembly connectable to an operating arm of a machine for performing work functions
RU2106146C1 (ru)	1995-07-17	1998-03-10	Институт элементоорганических соединений РАН	Средство для подавления опухолевого роста
EP1227844A2 (en)	1999-10-29	2002-08-07	Pharmacyclics, Inc.	Compositions for treating atheroma and neoplastic tissue
US7579338B2 (en)	1999-10-29	2009-08-25	Pharmacyclics, Inc.	Methods and compositions for treating atheroma, tumors and other neoplastic tissues
JP2003012547A (ja) *	2001-06-27	2003-01-15	Meiji Seika Kaisha Ltd	インスリン依存性糖尿病の診断剤および治療剤
CN103405769A (zh) *	2013-03-07	2013-11-27	北京亿仁赛博医疗科技研发中心有限公司	光敏剂在制备治疗疾病的病毒灭活药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5457183A (en) *	1989-03-06	1995-10-10	Board Of Regents, The University Of Texas System	Hydroxylated texaphyrins
US5419760A (en) *	1993-01-08	1995-05-30	Pdt Systems, Inc.	Medicament dispensing stent for prevention of restenosis of a blood vessel
US6008211A (en) *	1995-07-27	1999-12-28	Pdt Pharmaceuticals, Inc.	Photoactivatable compounds comprising benzochlorin and furocoumarin
US5913884A (en) *	1996-09-19	1999-06-22	The General Hospital Corporation	Inhibition of fibrosis by photodynamic therapy

1999
- 1999-07-05 AR ARP990103250A patent/AR019226A1/es unknown
- 1999-07-06 KR KR1020017000150A patent/KR20010079498A/ko not_active Withdrawn
- 1999-07-06 CA CA002336134A patent/CA2336134A1/en not_active Abandoned
- 1999-07-06 AU AU48608/99A patent/AU4860899A/en not_active Abandoned
- 1999-07-06 WO PCT/US1999/015199 patent/WO2000001414A1/en not_active Ceased
- 1999-07-06 JP JP2000557860A patent/JP2002519390A/ja active Pending
- 1999-07-06 EP EP99932263A patent/EP1094840A1/en not_active Withdrawn
2001
- 2001-01-04 NO NO20010044A patent/NO20010044L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20010044D0 (no)	2001-01-04
CA2336134A1 (en)	2000-01-13
EP1094840A1 (en)	2001-05-02
WO2000001414A1 (en)	2000-01-13
NO20010044L (no)	2001-03-01
KR20010079498A (ko)	2001-08-22
AR019226A1 (es)	2001-12-26
AU4860899A (en)	2000-01-24

Publication	Publication Date	Title
Koudinova et al.	2003	Photodynamic therapy with Pd‐bacteriopheophorbide (TOOKAD): Successful in vivo treatment of human prostatic small cell carcinoma xenografts
US6827926B2 (en)	2004-12-07	Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
Dolmans et al.	2002	Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy
Zhou et al.	1988	An ultrastructural comparative evaluation of tumors photosensitized by porphyrins administered in aqueous solution, bound to liposomes or to lipoproteins
AU2001229674B2 (en)	2005-02-24	Local drug delivery using photosensitizer-mediated and electromagnetic radiation-enhanced vascular permeability
JPH08501301A (ja)	1996-02-13	血液における感光剤の皮膚を通しての生体内活性化
Milanesi et al.	1990	Zn (II)-phthalocyanine as a photodynamic agent for tumours. II. Studies on the mechanism of photosensitised tumour necrosis
JP2002534218A (ja)	2002-10-15	非侵襲性の脈管療法
JP2002534219A (ja)	2002-10-15	標的細胞の経皮的な光力学的処置
JP2003508124A (ja)	2003-03-04	長期間光活性化癌治療
Neave et al.	1988	Hematoporphyrin uptake in atherosclerotic plaques: therapeutic potentials
Abels et al.	1997	Targeting of the tumor microcirculation by photodynamic therapy with a synthetic porphycene
Ayaru et al.	2005	Photodynamic therapy for pancreatic and biliary tract carcinoma
Rovers et al.	1999	Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra (hydroxyphenyl) chlorin (mTHPC), in a rat model
Nagae et al.	2001	Endovascular photodynamic therapy using mono‐L‐aspartyl‐chlorin e6 to inhibit Intimal hyperplasia in balloon‐injured rabbit arteries
Schaffer et al.	2003	Porphyrins as radiosensitizing agents for solid neoplasms
JP2002519390A (ja)	2002-07-02	マクロファージ媒介疾患におけるテキサフィリンの使用
Adili et al.	1998	Photodynamic therapy with local photosensitizer delivery inhibits experimental intimal hyperplasia
Lin et al.	2018	Photodynamic therapy of balloon-injured rat carotid arteries using indocyanine green
US20020115649A1 (en)	2002-08-22	Use of texaphyrins in macrophage-mediated disease
Osaki et al.	2009	Efficacy of antivascular photodynamic therapy using benzoporphyrin derivative monoacid ring A (BPD-MA) in 14 dogs with oral and nasal tumors
CN107613962B (zh)	2021-02-09	血清稳定组合物和用于光触发的材料释放的方法
Herman et al.	1990	Trimodality therapy (drug/hyperthermia/radiation) with BCNU or mitomycin C
WO2000001413A1 (en)	2000-01-13	Intracellular sensitizers for sonodynamic therapy
Yoshida et al.	1992	Photoactivated Photofrin II: astrocytic swelling precedes endothelial injury in rat brain

Legal Events

Date	Code	Title	Description
2006-03-30	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060329
2006-09-05	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060904

Date

Code

Title

Description

2006-03-30

A131

Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060329

2006-09-05

A02

Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060904